Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

75.41 -0.47 (-0.62%)
Streaming Delayed Price Updated: 12:02 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
From Glaukos Corporation
Via Business Wire
Glaukos Corporation Announces First Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Announces the Release of its 2021 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos: Q4 Earnings Insights
Glaukos (NYSE:GKOS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos... 
Via Benzinga
Earnings Scheduled For February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
Analyst Ratings For Glaukos
Glaukos (NYSE:GKOS) has observed the following analyst ratings within the las... 
Via Benzinga
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
From Glaukos Corporation
Via Business Wire
Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View
Sight Sciences Inc (NASDAQ: SGHT) has treated the first patient in the TRIDENT trial evaluating OMNI Surgical System compared to Glaukos Corp's (NYSE... 
Via Benzinga
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
From Glaukos Corporation
Via Business Wire
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
From Glaukos Corporation
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Glaukos Announces Executive Leadership Changes
From Glaukos Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen... 
Via Benzinga
Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile
Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The... 
Via Benzinga
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
From Glaukos Corporation
Via Business Wire
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
From Glaukos Corporation
Via Business Wire
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
From Glaukos Corporation
Via Business Wire
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher; All Eyes On Jobs Report
Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the key jobs data for December. Investors are awaiting earnings results from Acuity Brands,... 
Via Benzinga
5 Stocks To Watch For January 7, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects Acuity Brands, Inc. (NYSE: AYI) to report quarterly earnings at $2.41 per share on revenue of $... 
Via Benzinga
Glaukos Announces FDA 510(k) Clearance of iPRIME™
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
From Glaukos Corporation
Via Business Wire
Glaukos Corp (GKOS) FY 2021 Earnings Call Transcript
GKOS earnings call for the period ending November 29, 2021. 
Via The Motley Fool
Topics Earnings
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.